Personalized medicine in COPD treatment
- First Online:
- 504 Downloads
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and not all patients respond to all currently available drugs. The importance of personalized treatment of COPD is increasingly recognized. The new GOLD guidelines have moved the principles of treatment of stable COPD forward by including concepts of symptoms and risks into the decision for therapy. COPD phenotypes are the basis of personalized treatment in clinical practice. Consensus has been reached concerning several phenotypes: phenotypes according to the evaluation of image; the frequent exacerbator and infrequent exacerbator; asthma and COPD overlap syndrome; and the persistent systemic inflammation phenotype. These phenotypes can help clinicians identify patients that respond to specific pharmacological interventions. Comorbidities and other factors, such as social and economic status, must also be considered. Future research needs to validate potential phenotypes in longitudinal studies, and examine the responses of different phenotypes to existing and future therapies.
KeywordsChronic obstructive pulmonary disease Personalized medicine Phenotype Guideline
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.•Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: revised 2014. Available from: http://www.goldcopd.org. GOLD is the most important document of COPD, and the new version of GOLD is a tentative move towards personalized treatment for patients with COPD.
- 2.•Han MK et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598–604. This clinical commentary gave a clear definition of COPD phenotype, and proposed that COPD phenotypes should be associated with clinically meaningful outcomes. This more focused definition allows for classification of patients into distinct prognostic and therapeutic subgroups for both clinical and research purposes.PubMedCrossRefGoogle Scholar
- 10.•Hurst JR et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38. This analysis was based on data collected as part of the ECLIPSE observational study and analyzed the frequency and associations of exacerbation in 2,138 patients. This finding supports the hypothesis that patients who are more subject to frequent exacerbations have a distinct susceptibility phenotype.PubMedCrossRefGoogle Scholar
- 12.Uzun S, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.Lancet Respir Med. 2014 Apr 15. [Epub ahead of print].Google Scholar
- 32.National Health and Family Planning Commission. China Health Statistical Yearbook, 2011. http://www.moh.gov.cn/htmlfiles/zwgkzt/ptjnj/year2011/index2011.html (accessed Feb 1, 2014).